Researchers have uncovered the link to increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE) condition. Interferon-alpha (IFN-a) is shown to be the cause of this increased risk. For the first time, IFN-a priming was shown to promote lipid uptake and foam cell formation - a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE. Findings of this research is published in the February issue of Arthritis & Rheumatism.
SLE or lupus is a chronic, multisystem autoimmune disease that causes wide-spread inflammation in the body and can affect multiple organs. The Lupus Foundation of American estimates that up to 1.5 million Americans and more than 5 million people worldwide have some form of lupus (systemic, discoid, or drug-induced), which occurs more frequently in women. While prior studies have established that SLE patients demonstrated an increased incidence of premature atherosclerosis, they do not explain what may cause the greater cardiovascular risk.
"Although traditional risk factors such as hypertension, high cholesterol, and diabetes mellitus are thought to be important in mediating an increased risk for atherosclerosis in SLE, they fail to adequately explain the higher incidence of atherosclerotic diseases in SLE patients," said Nan Shen, M.D., Director of the Shanghai Institute of Rheumatology at Ren Ji Hospital and lead author of the study. To further investigate the cause of premature atherosclerosis in SLE, researchers recruited 42 patients with lupus and 42 healthy volunteers for their study. Blood samples were taken from all participants and peripheral blood monocytes were isolated and analyzed. Peripheral blood mononuclear cells (PBMCs) play an important role in the immune system's ability to fight infection.
Dr. Shen concluded, "Our findings further understanding of the mechanisms involved in the development of atherosclerosis in autoimmune disease and may provide potential therapeutic targets for the prevention and treatment of premature cardiovascular disease in lupus patients."